Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

Summary

The purpose of this study is to explore the overall safety profile and durability of efficacy of Engensis (VM202) in painful diabetic peripheral neuropathy. All subjects still in follow-up for the VMDN-003 study or who have completed the Day 270 visit within the prior 90 days will be approached to enroll in the long-term safety extension study.

Timeline

Start

2019-02-04

Primary completion

2019-07-24

Completion

2019-07-24

Drugs

Indications